medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-1-2-46-55medsovet-841Research ArticleКАРДИОЛОГИЯCARDIOLOGYВыбор антигипертензивного препарата для лечения артериальной гипертонииChoosing antihypertensive drug for the treatment of hypertensionОстроумоваО. Д.OstroumovaO. D.noemail@neicon.ruКопченовИ. И.KopchyonovI. I.noemail@neicon.ruМГСМУ им. А.И. ЕвдокимоваРоссияthe Evdokimov Moscow State University of Medicine and DentistryRussian Federation20133012201301-24655Copyright © Остроумова О.Д., Копченов И.И., 20132013Остроумова О.Д., Копченов И.И.Ostroumova O.D., Kopchyonov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/841

В статье представлены современные подходы к дифференцированному выбору антигипертензивных препаратов. Описаны преимущества и ограничения основных 5 классов антигипертензивных медикаментов. Приводятся данные о выборе препарата внутри класса с учетом конкретных клинических ситуаций.

The article tells about modern approaches to differentiated choice of antihypertensive drugs. The advantages and limitations of five key classes of antihypertensive medications are described. The authors share data on the choice of drug within the class taking into account specific clinical situations.

артериальная гипертонияингибиторы ангиотензинпревращающего ферментадиуретикибета-блокаторыантагонисты кальцияблокаторы рецепторов к ангиотензину IIфозиноприллизиноприламлодипинлозартаниндапамидhypertensionACE inhibitorsdiureticsbeta-blockerscalcium channel blockersangiotensin II receptor antagonistsfosinoprillisinoprilamlodipinelosartanindapamideReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5–26.Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5–26.Клиническая фармакология. Под ред. В.Г. Кукеса, издание 4, М.: «ГЭОТАР-Медиа», 2008. С. 321–396, 458–479.Клиническая фармакология. Под ред. В.Г. Кукеса, издание 4, М.: «ГЭОТАР-Медиа», 2008. С. 321–396, 458–479.Rizzoni D., Muiesan M.L., Porteri E. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J. Hypertens., 1997; 15 (2): 197-204.Rizzoni D., Muiesan M.L., Porteri E. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J. Hypertens., 1997; 15 (2): 197-204.Balázsi I., Takács J. The effect of lisinopril on hypertensive patients suffering in diabetic nephropathy Diabetologia Hungarica, 1999; 7.(N2.): 101-106.Balázsi I., Takács J. The effect of lisinopril on hypertensive patients suffering in diabetic nephropathy Diabetologia Hungarica, 1999; 7.(N2.): 101-106.Kawahara J., Hsieh ST., Tanaka S. et al. Effects of lisinopril on lipid peroxidation, cell membrane fatty acids, and insulin sensitivity in essential hypertension with impaired glucose tolerance. Am J Hypertens 1994; 7: 23A.Kawahara J., Hsieh ST., Tanaka S. et al. Effects of lisinopril on lipid peroxidation, cell membrane fatty acids, and insulin sensitivity in essential hypertension with impaired glucose tolerance. Am J Hypertens 1994; 7: 23A.Asselbergs F.W., Diercks G.F.H., Hillege H.L. et al. for the Prevention of Renal and Vascular Endstage Disease InterventionalTrial (PREVEND IT) Investigators. Effect of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria // Circulation. – 2004. – Vol. 110. – P. 2809-2816.Asselbergs F.W., Diercks G.F.H., Hillege H.L. et al. for the Prevention of Renal and Vascular Endstage Disease InterventionalTrial (PREVEND IT) Investigators. Effect of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria // Circulation. – 2004. – Vol. 110. – P. 2809-2816.Diercks G.F., Janssen W.M., van Boven A.J. et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]) // Amer. J. Cardiology. – 2000. – Vol. 86. – P. 635-638.Diercks G.F., Janssen W.M., van Boven A.J. et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]) // Amer. J. Cardiology. – 2000. – Vol. 86. – P. 635-638.Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Меdia Меdica, 2004. – 163c.Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Меdia Меdica, 2004. – 163c.Reisin E. TROPHY study. Hypertens. 1997; 30 [part 1]: P.140-145.Reisin E. TROPHY study. Hypertens. 1997; 30 [part 1]: P.140-145.Zancetti A., Crepaldi G., Bond G. et al. on behalf of PHYLLYS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorthiazide with or without lipid lowering with pravastatin on progression of asymptomatic carotid atherosclerosis. Princioal results of PHYLLIS – a randomized double-blind trial // Stroke. – 2004. – Vol. 35. – P. 2807-2812.Zancetti A., Crepaldi G., Bond G. et al. on behalf of PHYLLYS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorthiazide with or without lipid lowering with pravastatin on progression of asymptomatic carotid atherosclerosis. Princioal results of PHYLLIS – a randomized double-blind trial // Stroke. – 2004. – Vol. 35. – P. 2807-2812.Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. //Lancet.– 2002– 359(9311) – P. 995–1003.Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. //Lancet.– 2002– 359(9311) – P. 995–1003.Brenner B.M., Cooper M.E., de Zeeuw D., Grunfeld J.–P., Keane W.F., Kurokawa K., McGill J.B., Mitch W.E., Parving H.H., Remuzzi G., Ribeiro A.B., Schluchter M.D., Snavely D., Zhang Z., Simpson R., Ramjit D., Shahinfar S: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL). JRAAS 2000;1:328–35.Brenner B.M., Cooper M.E., de Zeeuw D., Grunfeld J.–P., Keane W.F., Kurokawa K., McGill J.B., Mitch W.E., Parving H.H., Remuzzi G., Ribeiro A.B., Schluchter M.D., Snavely D., Zhang Z., Simpson R., Ramjit D., Shahinfar S: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL). JRAAS 2000;1:328–35.Dang A., Zhang Y., Liu G. et al: Effects of losartan and irbesartan on serum uric asid in hipertensiv patients with hyperuricaemia in Chinese population. J hum Hypertense 2006; 20:45–49.Dang A., Zhang Y., Liu G. et al: Effects of losartan and irbesartan on serum uric asid in hipertensiv patients with hyperuricaemia in Chinese population. J hum Hypertense 2006; 20:45–49.Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum, 2006; Том 8 (№11): 113–117.Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum, 2006; Том 8 (№11): 113–117.Pitt B., Byington R.P., Furberg C.D. et al. (for the PREVENT investigators). Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102 (13): 1503–10.Pitt B., Byington R.P., Furberg C.D. et al. (for the PREVENT investigators). Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102 (13): 1503–10.Преображенский Д.В., Сидоренко Б.А. Дифференциальная медикаментозная терапия при артериальной гипертензии. Сonsilium Medicum. 2001; Том 3 (10): 83–87.Преображенский Д.В., Сидоренко Б.А. Дифференциальная медикаментозная терапия при артериальной гипертензии. Сonsilium Medicum. 2001; Том 3 (10): 83–87.Passeron J., Panly N., Despart J. International multicentre study of indapamide in the treatment of essential arterial hypertension. Postgrad. Med. J., 1981; 57: 53–64.Passeron J., Panly N., Despart J. International multicentre study of indapamide in the treatment of essential arterial hypertension. Postgrad. Med. J., 1981; 57: 53–64.

The authors declare that there are no conflicts of interest present.